Summary of COVID-19 darunavir studies


1. Kim et al., Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection
42 patient darunavir late treatment study: 87% lower mortality (p=0.009).
Retrospective 110 critically ill COVID-19 patients in South Korea showing lower mortality with darunavir/cobicistat treatment.
Dec 2020, Yonsei Medical J., https://eymj.org/DOIx.php?id=10.3349/ymj.2020.61.9.826, https://c19p.org/kim25

2. Nicolini et al., Reply to: “Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19”
328 patient darunavir late treatment study: 32% higher mortality (p=0.21).
Retrospective 328 hospitalized COVID-19 patients in Italy showing no mortality benefit with darunavir/ritonavir treatment.
Jul 2020, Open Forum Infectious Diseases, https://academic.oup.com/ofid/article/doi/10.1093/ofid/ofaa321/5877884, https://c19p.org/nicolini

3. Di Castelnuovo et al., Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study
2,303 patient darunavir late treatment study: 89% higher mortality (p<0.0001).
Retrospective 3,451 hospitalized COVID-19 patients in Italy showing higher mortality with darunavir/cobicistat.
Jun 2021, Frontiers in Medicine, https://www.frontiersin.org/articles/10.3389/fmed.2021.639970/full, https://c19p.org/dicastelnuovo3

4. Chen et al., Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19
30 patient darunavir early treatment RCT: 22% worse viral clearance (p=0.64).
RCT 30 mild COVID-19 patients showing no benefit of darunavir/cobicistat compared to standard care for viral clearance.
Jun 2020, Open Forum Infectious Diseases, https://academic.oup.com/ofid/article/doi/10.1093/ofid/ofaa241/5860459, https://c19p.org/chen37

5. Milic et al., Darunavir/Cobicistat Is Associated with Negative Outcomes in HIV-Negative Patients with Severe COVID-19 Pneumonia
273 patient darunavir late treatment study: 150% higher mortality (p=0.0001) and 48% higher combined mortality/intubation (p=0.03).
Retrospective 273 hospitalized COVID-19 patients showing higher mortality with darunavir/cobicistat treatment.
Mar 2021, AIDS Research and Human Retroviruses, https://www.liebertpub.com/doi/10.1089/aid.2020.0305, https://c19p.org/milic